Skip to main content
Fig. 2 | Molecular Neurodegeneration

Fig. 2

From: Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation

Fig. 2

Neuropathology analysis of LV-TLR2-delivered non-tg and α-syn-tg mice. Either LV-control or LV-TLR2 was injected into the hippocampus of non-tg or α-syn-tg mice (D line). a–d Representative images from immunohistochemical staining of α-synuclein (a), Iba-1 (b), GFAP (c), and NeuN (d) in the neocortex and hippocampus of lentiviral vector-delivered mice. The level of α-synuclein (a) or GFAP (c) was analyzed in the neocortex and hippocampus of the mice by optical density quantification. The number of Iba-1 (b) or NeuN (d) positive cell was counted in neocortex and hippocampus of the mice. Data are mean ± SEM (n = 6 per group). *p < 0.05, **p < 0.01, and ***p < 0.001; one way ANOVA. Scale bars, 250 μm (low magnification) and 25 μm (high magnification)

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326